{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T07:26:03Z","timestamp":1773300363653,"version":"3.50.1"},"reference-count":63,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2012,10,5]],"date-time":"2012-10-05T00:00:00Z","timestamp":1349395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Muscle and Nerve"],"published-print":{"date-parts":[[2013,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction:<\/jats:title><jats:p>Myopathy is the most common side effect of statins. Because nitric oxide (NO) has a key role in regulating skeletal muscle function, we studied whether the NO\u2010donating atorvastatin NCX 6560 could show a better profile on skeletal muscle function and structure compared with atorvastatin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>C57BL\/6 mice received atorvastatin 40 mg\/kg\/day or an equivalent dose of NCX 6560 for 2 months. Muscle function assessed by treadmill test, serum creatine kinase (CK) activity, citrate synthase (CS) activity, and muscle histology were evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Atorvastatin significantly (<jats:italic>P<\/jats:italic> &lt; 0.001) reduced muscle endurance, increased serum CK by 6\u2010fold, and induced muscle fiber atrophy. Conversely, NCX 6560 preserved muscle function, prevented CK increase and did not modify muscle structure. Interestingly, atorvastatin reduced CS activity, a marker for mitochondrial function, in gastrocnemius, diaphragm, and heart, whereas NCX 6560 prevented such decrease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>These findings suggest that NO may prevent statin\u2010induced myopathy. Muscle Nerve, 2013<\/jats:p><\/jats:sec>","DOI":"10.1002\/mus.23465","type":"journal-article","created":{"date-parts":[[2012,5,22]],"date-time":"2012-05-22T19:41:12Z","timestamp":1337715672000},"page":"72-80","source":"Crossref","is-referenced-by-count":11,"title":["Nitric oxide prevents atorvastatin\u2010induced skeletal muscle dysfunction and alterations in mice"],"prefix":"10.1002","volume":"47","author":[{"given":"Giuseppe","family":"D'Antona","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Mascaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angela","family":"Monopoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Miglietta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ennio","family":"Ongini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Bottinelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,10,5]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(03)00474-0"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.164.12.1313"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2006.09.020"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02030-2"},{"key":"e_1_2_6_6_2","first-page":"1421","article-title":"Factors affecting patient compliance with antihyperlipidemic medications in an HMO population","volume":"10","author":"Sung JC","year":"1998","journal-title":"Am J Manag Care"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2011.01.052"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.5.553"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-005-5686-z"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1517\/14740338.2011.540568"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-008-0636-7"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.22205"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1106689"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1080\/01926230590908213"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.02.049"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2008.05.021"},{"key":"e_1_2_6_17_2","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3949\/ccjm.78a.10073","article-title":"Statin myopathy: a common dilemma not reflected in clinical trials","volume":"6","author":"Fernandez G","year":"2011","journal-title":"Cleve Clin J Med"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-009-0077-8"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/372546a0"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(93)81210-Q"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"11204","DOI":"10.1074\/jbc.271.19.11204","article-title":"Neuronal nitric\u2010oxide synthase\u2010mu, an alternatively spliced isoform expressed in differentiated skeletal muscle","volume":"19","author":"Silvagno F","year":"1996","journal-title":"J Biol Chem"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-8966(01)00215-2"},{"key":"e_1_2_6_23_2","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1126\/science.1079368","article-title":"Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide","volume":"5608","author":"Nisoli E","year":"2003","journal-title":"Science"},{"key":"e_1_2_6_24_2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1152\/physrev.2001.81.1.209","article-title":"Physiology of nitric oxide in skeletal muscle","volume":"1","author":"Stamler JS","year":"2001","journal-title":"Physiol Rev"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.niox.2009.08.002"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/dvdy.21012"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2008.09.005"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0608277104"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1096\/fj.08-115618"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.03300"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2005.02.010"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200105110"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2010.07.006"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707142"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2007.05.014"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0401996101"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01605.x"},{"key":"e_1_2_6_38_2","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/nature04422","article-title":"Facioscapulohumeral muscular dystrophy in mice overexpressing FRG1","volume":"7079","author":"Gabellini D","year":"2006","journal-title":"Nature"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1479"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2007.09.016"},{"key":"e_1_2_6_41_2","doi-asserted-by":"crossref","first-page":"C585","DOI":"10.1152\/ajpcell.2001.281.2.C585","article-title":"Response to caffeine and ryanodine receptor isoforms in mouse skeletal muscles","volume":"2","author":"Rossi R","year":"2001","journal-title":"Am J Physiol Cell Physiol"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2002.027375"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1113\/expphysiol.2003.002609"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.2337\/db07-1623"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvs100"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6107(00)00006-7"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.106.118331"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2007.12.010"},{"key":"e_1_2_6_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2011.01.022"},{"key":"e_1_2_6_50_2","first-page":"616","article-title":"Pharmacodynamics and pharmacokinetic\u2010pharmacodynamic relationships of atorvastatin, an HMG\u2010CoA reductase inhibitor","volume":"6","author":"Stern RH","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-199309000-00012"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/kfi305"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2005.10.108"},{"key":"e_1_2_6_54_2","first-page":"85","article-title":"Mitochondrial alterations in muscle biopsies of patients on statin therapy","volume":"1","author":"Gambelli S","year":"2004","journal-title":"J Submicrosc Cytol Pathol"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1620\/tjem.99.225"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.200507083"},{"key":"e_1_2_6_57_2","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E02-01-0062"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbabio.2003.06.008"},{"key":"e_1_2_6_59_2","article-title":"Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a 'mitohormesis' mechanism involving reactive oxygen species and PGC\u20101","author":"Bouitbir J","year":"2011","journal-title":"Eur Heart J"},{"key":"e_1_2_6_60_2","first-page":"3940","article-title":"The muscle\u2010specific ubiquitin ligase atrogin\u20101\/MAFbx mediates statin\u2010induced muscle toxicity","volume":"117","author":"Hanai J","year":"2007","journal-title":"J Clin Invest"},{"key":"e_1_2_6_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00809.x"},{"key":"e_1_2_6_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2011.05.003"},{"key":"e_1_2_6_63_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2005.03.023"},{"key":"e_1_2_6_64_2","first-page":"A14267","article-title":"NCX 6560, a novel nitric oxide donating atorvastatin with a promising safety and efficacy profile: a randomised, double blind placebo and active control study","volume":"122","author":"Dijan JP","year":"2010","journal-title":"Circulation"}],"container-title":["Muscle &amp; Nerve"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmus.23465","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mus.23465","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T03:27:14Z","timestamp":1697513234000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mus.23465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10,5]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,1]]}},"alternative-id":["10.1002\/mus.23465"],"URL":"https:\/\/doi.org\/10.1002\/mus.23465","archive":["Portico"],"relation":{},"ISSN":["0148-639X","1097-4598"],"issn-type":[{"value":"0148-639X","type":"print"},{"value":"1097-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10,5]]}}}